Country
United Kingdom
UK-based Oxular Ltd has secured $37 million in venture finance to advance its lead product for diabetic macular edema (DME) into Phase 2 as well as support earlier stage ophthalmologic products.
Full text available to subscribers only. Click here for information on subscribing to MedNous.